Knockout of Fzd4 in the non‐small cell lung cancer (NSCLC) cell line A549 followed by replenishment of Fzd4 glycosylation site mutants inhibited the growth and migration ability of A549 cells in vitro and in vivo. Here, FZD4 is linked to non-small cell lung carcinoma.